Ask AI
ProCE Banner Activity

Managing EGFR-Mutated Non-Small-Cell Lung Cancer in Today’s Clinic: Expert Answers to Frequently Asked Questions

Podcast
Listen to experts answer questions from a live meeting series on optimizing the care of patients with EGFR-mutated non-small-cell lung cancer in the clinic today.

Released: September 28, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Faculty Disclosure

Primary Author

Ryan D. Gentzler, MD, MS

Thoracic Medical Oncologist
Professor of Medicine
Division of Hematology/Oncology
University of Virginia
Charlotteville, Virginia

Ryan D. Gentzler, MD, MS: researcher: Alliance Foundation Trials, AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, ECOG-ACRIN, Helsinn, Hoosier Cancer Research Network, Janssen, Jounce, Merck, Mirati, NCI, Pfizer, RTI International, Takeda; speaker: OncLive, Rockpointe, Targeted Oncology, Total Health Conferencing; advisor: AstraZeneca, BluePrint Medicines, Daiichi Sankyo, Gilead Sciences, Janssen, Jazz Pharmaceuticals, Mirati, Oncocyte, Pfizer, Sanofi.

Jonathan Riess, MD, MS

Associate Professor
Division of Hematology-Oncology
Department of Internal Medicine
UC Davis
Medical Director
Thoracic Oncology
UC Davis Comprehensive Cancer Center
Sacramento, California

Jonathan Riess, MD: consultant/advisor/speaker: Bristol-Myers Squibb, BeiGene, Blueprint, Boehringer Ingelheim, Daiichi Sankyo, Genentech, Jazz, Janssen, Novartis, Regeneron; researcher: AstraZeneca, GlaxoSmithKline, Merck, Novartis, Revolution Medicines, Spectrum.